稳定性冠心病初始侵入性与保守治疗的远期生存分析
ISCHEMIA试验延长随访至中位5.7年,比较初始侵入性策略与初始保守策略对慢性冠心病伴中重度缺血患者的死亡影响。结果显示全因死亡率无差异,但侵入性策略心血管死亡率更低而非心血管死亡率更高。
要点
- 全因死亡率两组无差异,7年发生率侵入性12.7% vs 保守13.4%,校正HR 1.00(95%CI 0.85-1.18)。
- 心血管死亡率侵入性策略更低:7年6.4% vs 8.6%,校正HR 0.78(95%CI 0.63-0.96)。
- 非心血管死亡率侵入性策略更高:7年5.6% vs 4.4%,校正HR 1.44(95%CI 1.08-1.91)。
核心结论
- 初始侵入性策略与初始保守策略相比全因死亡率无差异,但心血管死亡率更低而非心血管死亡率更高。
研究设计与样本
- ISCHEMIA试验随机对照研究,纳入5179例慢性冠心病伴中重度缺血患者,中位随访5.7年,延长随访截至2021年12月。
主要发现
- 全因死亡率两组无差异:7年发生率侵入性12.7% vs 保守13.4%,校正HR 1.00(95%CI 0.85-1.18)。
- 心血管死亡率侵入性更低:7年6.4% vs 8.6%,校正HR 0.78(95%CI 0.63-0.96)。
- 非心血管死亡率侵入性更高:7年5.6% vs 4.4%,校正HR 1.44(95%CI 1.08-1.91)。
- 预设亚组(包括多支冠状动脉病变)未见治疗效应异质性。
关键数值与推荐
- 纳入标准:中重度缺血、射血分数≥35%、无近期急性冠脉综合征;排除无法接受的心绞痛患者。
临床怎么用
- 对于慢性冠心病伴中重度缺血且症状可接受的患者,初始侵入性策略不改善总体生存,但可能降低心血管死亡风险,需权衡非心血管死亡风险增加。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The ISCHEMIA trial (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches) compared an initial invasive versus an initial conservative management strategy for patients with chronic coronary disease and moderate or severe ischemia, with no major difference in most outcomes during a median of 3.2 years. Extended follow-up for mortality is ongoing. METHODS: ISCHEMIA participants were randomized to an initial invasive strategy added to guideline-directed medical therapy or a conservative strategy. Patients with moderate or severe ischemia, ejection fraction ≥35%, and no recent acute coronary syndromes were included. Those with an unacceptable level of angina were excluded. Extended follow-up for vital status is being conducted by sites or through central death index search. Data obtained through December 2021 are included in this interim report. We analyzed all-cause, cardiovascular, and noncardiovascular mortality by randomized strategy, using nonparametric cumulative incidence estimators, Cox regression models, and Bayesian methods. Undetermined deaths were classified as cardiovascular as prespecified in the trial protocol. RESULTS: Baseline characteristics for 5179 original ISCHEMIA trial participants included median age 65 years, 23% women, 16% Hispanic, 4% Black, 42% with diabetes, and median ejection fraction 0.60. A total of 557 deaths accrued during a median follow-up of 5.7 years, with 268 of these added in the extended follow-up phase. This included a total of 343 cardiovascular deaths, 192 noncardiovascular deaths, and 22 unclassified deaths. All-cause mortality was not different between randomized treatment groups (7-year rate, 12.7% in invasive strategy, 13.4% in conservative strategy; adjusted hazard ratio, 1.00 [95% CI, 0.85-1.18]). There was a lower 7-year rate cardiovascular mortality (6.4% versus 8.6%; adjusted hazard ratio, 0.78 [95% CI, 0.63-0.96]) with an initial invasive strategy but a higher 7-year rate of noncardiovascular mortality (5.6% versus 4.4%; adjusted hazard ratio, 1.44 [95% CI, 1.08-1.91]) compared with the conservative strategy. No heterogeneity of treatment effect was evident in prespecified subgroups, including multivessel coronary disease. CONCLUSIONS: There was no difference in all-cause mortality with an initial invasive strategy compared with an initial conservative strategy, but there was lower risk of cardiovascular mortality and higher risk of noncardiovascular mortality with an initial invasive strategy during a median follow-up of 5.7 years. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT04894877.
引用
- Hochman JS, Anthopolos R, Reynolds HR, et al. Survival After Invasive or Conservative Management of Stable Coronary Disease. Circulation. 2022. PMID: 36335918. doi:10.1161/CIRCULATIONAHA.122.062714
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。